16.10.2026
| 12:00-12:45 | Registration & Lunch |
| 12:45-13:00 | Welcome and Opening Remarks |
| 12:45-12:50 | Welcome – Michał Nowicki & Eleni Frangou |
| 12:50-13:00 | The changing epidemiology and treatment of glomerular diseases – Michał Nowicki |
| 13:00-14:30 | Session 1 – IgA Nephropathy: the evolving landscape |
| 13:00-13:30 | How do we optimize standard of care? – Izabela Zakrocka |
| 13:30-14:00 | Progress in IgAN: the approval status of drugs with positive Phase 3 results – Şafak Mirioğlu |
| 14:00-14:30 | The future of therapies in IgAN – Chee Kay Cheung |
| 14:30-15:00 | Coffee Break |
| 15:00-16:30 | Session 2 – ANCA-associated vasculitis |
| 15:00-15:30 | Complement inhibition in AAV – Annette Bruchfeld |
| 15:30-16:00 | Kidney risk scores: how did they evolve and how to implement them? – Ingeborg Bajema |
| 16:00-16:30 | The future of AAV therapies – Sarah Moran |
| 16:30-18:00 | Session 3 – Membranous nephropathy |
| 16:30-17:00 | Why do we need new endpoints in MN trials? (virtual) – Tobias B. Huber |
| 17:00-17:30 | Is rituximab the solution for all patients with MN? – Anna Matyjek |
| 17:30-18:00 | Trial landscape and outlook – Andreas Kronbichler |
